Core Insights - NewGenIvf Group Limited has received a valuation report from a Big Four global accounting firm, setting the fair value of its recently acquired advanced cytometry intellectual property at US$17.9 million, which boosts the company's net asset value (NAV) per share by approximately US$8.9 [1][2] - The acquisition marks a strategic shift for NewGen from traditional IVF services to a technology-driven model, aiming to generate high-margin, recurring revenue through licensing and supplying proprietary consumables [2][4] - NewGen is pursuing regulatory approvals to commercialize the technology and plans to establish an in-house R&D team to maintain its competitive edge in the growing fertility services market, particularly in the Asia Pacific region [3][4] Company Strategy - The acquisition of advanced cytometry technology positions NewGen as a technology leader in the fertility services industry, allowing it to provide exclusive, technology-backed solutions to partner clinics without requiring upfront investments [2][4] - The company aims to create a sustainable growth model through royalty-based revenue streams, enhancing its operational capabilities and unlocking immediate value for shareholders [4] Market Context - The global fertility services market is experiencing significant growth, with 1 in 6 couples worldwide affected by infertility, presenting a substantial opportunity for NewGen to capture market share [3]